Moderna, Inc. $MRNA Stock Purchased by Voya Investment Management LLC

Voya Investment Management LLC boosted its stake in shares of Moderna, Inc. (NASDAQ:MRNA – Free Report) by 6.4% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 381,195 shares of the company’s stock after purchasing an additional 22,843 shares during the quarter. Voya Investment Management LLC’s holdings in Moderna were worth $73,407,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. BlackRock Inc. acquired a new position in Moderna during the second quarter valued at $2,142,877,000. Theleme Partners LLP purchased a new stake in Moderna in the 2nd quarter worth about $564,272,000. Wellington Management Group LLP lifted its stake in Moderna by 4.4% in the 2nd quarter. Wellington Management Group LLP now owns 2,461,574 shares of the company’s stock worth $172,384,000 after acquiring an additional 103,977 shares in the last quarter. First Trust Advisors LP lifted its stake in Moderna by 59.3% in the 1st quarter. First Trust Advisors LP now owns 2,392,693 shares of the company’s stock worth $121,549,000 after acquiring an additional 891,072 shares in the last quarter. Finally, Merck & Co. Inc. acquired a new stake in Moderna during the 2nd quarter worth about $161,642,545. 75.33% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

MRNA has been the topic of several research analyst reports. TD Cowen reaffirmed a “buy” rating on shares of Moderna in a research note on Wednesday, October 21st. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $130.00 target price on shares of Moderna in a report on Wednesday, August 19th. Deutsche Bank assumed coverage on shares of Moderna in a research report on Friday, August 28th. They issued a “hold” rating and a $125.00 price target for the company. Argus upgraded shares of Moderna from a “hold” rating to a “buy” rating and set a $180.00 price target for the company in a report on Friday, August 28th. Finally, Bradesco Corretora upgraded shares of Moderna to an “outperform” rating in a report on Friday, August 28th. Six investment analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and four have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $120.25.

Read Our Latest Research Report on MRNA

Trending Headlines about Moderna

Here are a few of the latest headlines about MRNA:

  • Positive Sentiment: Moderna’s personalized melanoma vaccine, used with Merck’s Keytruda, reduced the risk of recurrence or death by 42% in a Phase 3 trial; further analysis showed a 58% reduction at six months. The results strengthen the case for Moderna’s oncology pipeline and were viewed by Morgan Stanley as clinical proof of concept. Cancer vaccine article
  • Neutral Sentiment: Morgan Stanley raised its price target from $95 to $200 but kept an “equal weight” rating, suggesting the firm sees limited near-term upside at the cited share price despite the higher target. Analyst outlook
  • Negative Sentiment: Moderna’s shares have been in a losing streak after a very large year-to-date rally, raising the prospect of profit-taking and higher expectations. The vaccine trial’s strong results have not prevented the stock from weakening, suggesting investors may be focused on valuation or how quickly the program can translate into revenue. Stock performance article

Moderna Price Performance

Shares of NASDAQ:MRNA opened at $196.79 on Thursday. The company has a current ratio of 3.62, a quick ratio of 3.47 and a debt-to-equity ratio of 0.52. Moderna, Inc. has a 1 year low of $22.28 and a 1 year high of $280.80. The business has a fifty day simple moving average of $205.61 and a 200 day simple moving average of $98.82. The firm has a market cap of $79.63 billion, a price-to-earnings ratio of -27.72 and a beta of 1.16.

Moderna (NASDAQ:MRNA – Get Free Report) last released its quarterly earnings data on Friday, November 6th. The company reported $0.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.10) by $1.48. Moderna had a negative return on equity of 25.79% and a negative net margin of 110.46%. The firm had revenue of $1.31 billion during the quarter, compared to analysts’ expectations of $890.25 million. During the same quarter last year, the firm earned ($0.51) earnings per share. The business’s revenue for the quarter was up 29.2% on a year-over-year basis. As a group, sell-side analysts predict that Moderna, Inc. will post -5.14 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, President Stephen Hoge sold 40,294 shares of Moderna stock in a transaction dated Monday, September 14th. The stock was sold at an average price of $144.13, for a total transaction of $5,807,574.22. Following the completion of the sale, the president directly owned 1,525,858 shares in the company, valued at $219,921,913.54. The trade was a 2.57% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO James M. Mock sold 34,836 shares of Moderna stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $134.49, for a total value of $4,685,093.64. Following the sale, the chief financial officer owned 59,375 shares of the company’s stock, valued at approximately $7,985,343.75. This represents a 36.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 275,626 shares of company stock valued at $50,776,076 in the last three months. Insiders own 10.80% of the company’s stock.

About Moderna

(Free Report)

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.

See Also

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA – Free Report).

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.